全文获取类型
收费全文 | 27746篇 |
免费 | 2126篇 |
国内免费 | 958篇 |
专业分类
耳鼻咽喉 | 200篇 |
儿科学 | 439篇 |
妇产科学 | 367篇 |
基础医学 | 3184篇 |
口腔科学 | 451篇 |
临床医学 | 2207篇 |
内科学 | 6108篇 |
皮肤病学 | 509篇 |
神经病学 | 1576篇 |
特种医学 | 237篇 |
外国民族医学 | 7篇 |
外科学 | 1998篇 |
综合类 | 2573篇 |
现状与发展 | 18篇 |
预防医学 | 548篇 |
眼科学 | 372篇 |
药学 | 6050篇 |
8篇 | |
中国医学 | 568篇 |
肿瘤学 | 3410篇 |
出版年
2024年 | 68篇 |
2023年 | 601篇 |
2022年 | 913篇 |
2021年 | 1331篇 |
2020年 | 1080篇 |
2019年 | 1020篇 |
2018年 | 1032篇 |
2017年 | 1000篇 |
2016年 | 871篇 |
2015年 | 990篇 |
2014年 | 1601篇 |
2013年 | 2662篇 |
2012年 | 1412篇 |
2011年 | 1665篇 |
2010年 | 1266篇 |
2009年 | 1378篇 |
2008年 | 1445篇 |
2007年 | 1294篇 |
2006年 | 1205篇 |
2005年 | 1116篇 |
2004年 | 930篇 |
2003年 | 817篇 |
2002年 | 641篇 |
2001年 | 549篇 |
2000年 | 420篇 |
1999年 | 410篇 |
1998年 | 354篇 |
1997年 | 326篇 |
1996年 | 277篇 |
1995年 | 270篇 |
1994年 | 208篇 |
1993年 | 179篇 |
1992年 | 155篇 |
1991年 | 151篇 |
1990年 | 165篇 |
1989年 | 109篇 |
1988年 | 94篇 |
1987年 | 76篇 |
1986年 | 67篇 |
1985年 | 125篇 |
1984年 | 101篇 |
1983年 | 79篇 |
1982年 | 94篇 |
1981年 | 75篇 |
1980年 | 53篇 |
1979年 | 40篇 |
1978年 | 35篇 |
1977年 | 18篇 |
1976年 | 16篇 |
1975年 | 15篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
Leukocyte rolling and firm adhesion at the venular endothelium are two discrete events in the cellular inflammatory response mediated via selectin and integrin adhesion molecules, respectively. The dependency of chemoattractant-induced firm leukocyte adhesion on the preceding rolling interaction was investigated in rat mesenteric microvessels through use of intravital microscopy. Leukocyte rolling was dose-dependently inhibited by systemic treatment with the sulphated polysaccharide fucoidin. The firm leukocyte adhesion following stimulation with the chemotactic peptide fMLP was similarly inhibited when fMLP challenge was performed subsequent to inhibition of leukocyte rolling by fucoidin. Thus, based on paired observations in single venules before and after fucoidin treatment, reduced rolling leukocyte flux prior to fMLP challenge was paralleled over a wide range by a proportional decrease in fMLP-induced leukocyte adhesion. The results demonstrate quantitatively a close relationship between the extent of leukocyte rolling and the magnitude of the subsequent firm adhesion response, and, that an initial rolling interaction is a precondition for firm adhesion to occur at physiological blood flow rates in vivo. 相似文献
52.
S. L. Nesterchuk N. S. Suleimanova E. R. Tkachenko L. V. Adamyan L. A. Marchenko G. T. Sukhikh 《Bulletin of experimental biology and medicine》1994,117(1):71-74
Potentialities of the flow cytornetry method in studies of the qualitative and quantitative composition of endometrial immunocompetent
cells are demonstrated. The studied leukocyte populations are found to occur in negligible quantities in the endometrium.
Translated fromByulleten' Eksperimental'noi Biologii i Meditsiny, Vol. 117, N
o
1, pp. 68–71, January, 1994. 相似文献
53.
ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS AND KININ METABOLISM: EVIDENCE THAT ACE INHIBITORS MAY INHIBIT A KININASE OTHER THAN ACE 总被引:1,自引:0,他引:1
Duncan J. Campbell 《Clinical and experimental pharmacology & physiology》1995,22(12):903-911
1. Angiotensin converting enzyme (ACE) converts angiotensin I to angiotensin II, and also metabolizes bradykinin-(1–9) to bradykinin-(1–7) and bradykinin-(1–7) to bradykinin-(1–5). Increases in endogenous kinin levels may contribute to the therapeutic effects of ACE inhibitors. 2. ACE inhibitors increase vascular levels of both bradykinin-(1–9) and its ACE cleavage product bradykinin-(1–7), at doses below the threshold for ACE inhibition, leading to the proposal that ACE inhibitors may also inhibit a non-ACE kininase which cleaves both kinin peptides; this non-ACE kininase may be the major pathway of kinin metabolism in the vasculature and some other tissues. 3. In support of this proposal, ACE inhibitors potentiate bradykinin-(1–9) effects at doses which have little or no effect on ACE activity, as indicated by angiotensin I conversion to angiotensin II. ACE inhibitors also potentiate the actions of ACE-resistant kinin analogues, which may be susceptible to metabolism by a non-ACE kininase. 4. Identification and characterization of the putative non-ACE kininase which is inhibited by ACE inhibitors may reveal novel approaches to the tissue-specific modulation of kinin levels. 相似文献
54.
基质金属蛋白酶及其抑制剂在子宫内膜癌的侵袭和转移中发挥着重要的作用。肿瘤的新生血管对肿瘤的发生、发展、转移及预后有着重要作用。微血管密度是衡量血管生成的定量指标。基质金属蛋白酶抑制剂可抑制血管的生成和MMPs对细胞外基质的降解。现将他们与子宫内膜癌的关系综述如下。 相似文献
55.
丹参对脑缺血再灌注区白细胞与内皮细胞粘附的影响 总被引:3,自引:0,他引:3
目的:研究丹参对脑缺血再灌注损伤后局灶区白细胞与内皮细胞粘附性变化及影响;方法:通过免疫荧光标记技术和显微超高速系统观察脑缺血再灌注及应用丹参后局灶白细胞粘附性的变化。结果:试验表明脑缺血再灌注损伤局部灶区微动脉白细胞附壁指数升高,白细胞与内皮细胞间断裂应力降低,粘附性显著下降。结论:研究结果表明,丹参可显著减轻脑缺血再灌注损伤后内皮细胞的粘附。 相似文献
56.
目的探讨123I-MIBG心肌显像在治疗前预测依那普利对扩张型心肌病(DCM)患者治疗效果的临床价值。方法对24例DCM患者于依那普利治疗前行早期(20min)及延迟(3h)123I-MIBG心肌显像,采用心/上纵隔(H/M)比和心脏放射性洗脱率(WR)作为相对半定量计数分析,与超声心功能参数进行对比。根据123I-MI-BG心肌显像延迟相的H/M分为3组延迟H/M≥1.7为组Ⅰ,1.5<延迟H/M<1.7为组Ⅱ,延迟H/M≤1.5为组Ⅲ。组Ⅰ和组Ⅱ在平均治疗4.5个月后重复以上检查。结果治疗前3组间超声心功能参数比较均无统计学差异。治疗后组Ⅰ的左室射血分数(LVEF)和左室收缩末径(LVDs)明显改善,早期H/M和延迟H/M均明显改善(P<0.05),而WR无明显变化。治疗后组Ⅱ的延迟H/M明显改善(P<0.05),而早期H/M和WR均无明显变化,心功能参数也无改善。组Ⅰ和组Ⅱ患者均能耐受依那普利治疗,而组Ⅲ患者均不能耐受依那普利治疗。结论123I-MIBG心肌显像在治疗前预测依那普利对DCM患者的治疗效果方面有一定价值。 相似文献
57.
A M Abdel Gader A A Al-Mishari S A Awadalla N M Buyuomi T Khashoggi M Al-Hakeem 《International journal of gynaecology and obstetrics》2006,95(3):248-253
OBJECTIVE: To clarify the role played by tissue factor pathway inhibitor (TFPI) in pregnancy hypertension. METHODS: Using enzyme-linked immunosorbent assays, hemostatic measurements were obtained for women with pre-eclampsia (n=51), nonproteinuric hypertension of pregnancy (n=62), postpartum pre-eclampsia 24 h after childbirth (n=31), and no hypertension (healthy pregnant controls, n=100). RESULTS: There was a significant increase in circulating free TFPI levels in women with pre-eclampsia (9.7+/-6.2 ng/mL) or nonproteinuric hypertension of pregnancy (8.3+/-5.3 ng/mL) compared with healthy controls (5.3+/-2.1 ng/mL). In women with pre-eclampsia the levels remained elevated after placental delivery (10.6+/-4.0 ng/mL). Free protein S levels were significantly higher in women with pre-eclampsia (40.0%+/-10.7%), nonproteinuric hypertension of pregnancy (37.1%+/-12.5%), or postpartum pre-eclampsia (39.3%+/-9.1%) than in healthy pregnant controls (32.2%+/-8.5%). CONCLUSION: Increased levels of the physiologically active free forms of TFPI and free protein S, 2 coagulation inhibitors, may protect women with pregnancy-induced hypertension from the risks of hemostatic activation. 相似文献
58.
Summary. Patients with mild or moderate haemophilia A usually have a mild bleeding disorder requiring only occasional treatment with factor VIII (FVIII) concentrates. The frequency of inhibitor development in such patients has been the subject of several recent surveys, which significantly modified our appreciation of this complication. Studies of the anti-FVIII antibodies provided an explanation for the different bleeding phenotypes observed in mild/moderate haemophilia A patients with inhibitors. Antibodies distinguishing between the patient's mutant FVIII and the normal wild-type FVIII were characterized, in addition to antibodies inhibiting completely or only partially FVIII activity. T lymphocytes recognizing FVIII and likely involved in the development of the immune response to FVIII were successfully identified. The FVIII peptides recognized by those FVIII-specific cells bind to many major histocompatibility complex (MHC) class II molecules, which may provide an explanation for the lack of strong association between MHC haplotypes and inhibitor development. Although these studies have advanced our understanding of the conditions leading to inhibitor development, further work is required to determine whether the mode of FVIII administration significantly influences inhibitor development. Further studies of the genetic factors are also required to fully understand the mechanisms leading to inhibitor development in patients with mild/moderate haemophilia A. 相似文献
59.
Alex W Wilson Stephen J Medhurst Claire I Dixon Nick C Bontoft Lisa A Winyard Kim T Brackenborough Jorge De Alba Christopher J Clarke Martin J Gunthorpe Gareth A Hicks Chas Bountra Daniel S McQueen Iain P Chessell 《European Journal of Pain》2006,10(6):537-549
Clinically, inflammatory pain is far more persistent than that typically modelled pre-clinically, with the majority of animal models focussing on short-term effects of the inflammatory pain response. The large attrition rate of compounds in the clinic which show pre-clinical efficacy suggests the need for novel models of, or approaches to, chronic inflammatory pain if novel mechanisms are to make it to the market. A model in which a more chronic inflammatory hypersensitivity phenotype is profiled may allow for a more clinically predictive tool. The aims of these studies were to characterise and validate a chronic model of inflammatory pain. We have shown that injection of a large volume of adjuvant to the intra-articular space of the rat knee results in a prolonged inflammatory pain response, compared to the response in an acute adjuvant model. Additionally, this model also results in a hypersensitive state in the presence and absence of inflammation. A range of clinically effective analgesics demonstrate activity in this chronic model, including morphine (3mg/kg, t.i.d.), dexamethasone (1mg/kg, b.i.d.), ibuprofen (30mg/kg, t.i.d.), etoricoxib (5mg/kg, b.i.d.) and rofecoxib (0.3-10mg/kg, b.i.d.). A further aim was to exemplify the utility of this chronic model over the more acute intra-plantar adjuvant model using two novel therapeutic approaches; NR2B selective NMDA receptor antagonism and iNOS inhibition. Our data shows that different effects were observed with these therapies when comparing the acute model with the model of chronic inflammatory joint pain. These data suggest that the chronic model may be more relevant to identifying mechanisms for the treatment of chronic inflammatory pain states in the clinic. 相似文献
60.
2005~2007年我国非甾体抗炎药市场应用分析 总被引:1,自引:0,他引:1
目的:以骨骼肌肉系统使用非甾体抗炎药物为例,分析该类药物在2005~2007年的销售数量、销售金额及生产厂家风云榜。方法:采用药物分类累加的方法统计2005~2007年非甾体抗炎药的销售数量和金额排序,并对前10位药品销售数量和金额对比,及前10位厂家对比。结果:双氯芬酸稳居销售榜首,美洛昔康、布洛芬等药物位居其后。结论:新一代的非甾体抗炎药已经占据主要市场,各类药物各有特色,但是仍需注意其消化系统及心血管系统的不良反应。 相似文献